BR0007047A - Composição farmacêutica para o tratamento de doença imune - Google Patents
Composição farmacêutica para o tratamento de doença imuneInfo
- Publication number
- BR0007047A BR0007047A BR0007047-5A BR0007047A BR0007047A BR 0007047 A BR0007047 A BR 0007047A BR 0007047 A BR0007047 A BR 0007047A BR 0007047 A BR0007047 A BR 0007047A
- Authority
- BR
- Brazil
- Prior art keywords
- antigen
- treatment
- pharmaceutical composition
- immune
- disease
- Prior art date
Links
- 208000026278 immune system disease Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 201000008482 osteoarthritis Diseases 0.000 abstract 2
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract 1
- 101001042104 Homo sapiens Inducible T-cell costimulator Proteins 0.000 abstract 1
- 102100021317 Inducible T-cell costimulator Human genes 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 206010070834 Sensitisation Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000024908 graft versus host disease Diseases 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 230000008313 sensitization Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000001960 triggered effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Patente de Invenção: <B>"COMPOSIçãO FARMACêUTICA PARA O TRATAMENTO DE DOENçA IMUNE"<D>. Foi descoberto que um anticorpo contra AILIM (alternativamente, chamada antígeno JTT-1, antígeno JTT-2, ICOS e 8F4) tem um efeito terapêutico significativo sobre artrose, por exemplo, artrite reumatóide e osteoartrite, doença de enxerto versus hospedeiro, rejeição imunológica de enxerto, inflamação (hepatite e doenças inflamatórias do instestino), estado de doença acompanhado pela excessiva produção de um anticorpo contra um antígeno estranho acionado por sensibilização imunológica pelo antígeno
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP24267299 | 1999-08-30 | ||
| JP2000254680 | 2000-08-24 | ||
| PCT/JP2000/005868 WO2001015732A1 (fr) | 1999-08-30 | 2000-08-30 | Traitements de maladies immunitaires |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0007047A true BR0007047A (pt) | 2001-07-31 |
Family
ID=26535864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0007047-5A BR0007047A (pt) | 1999-08-30 | 2000-08-30 | Composição farmacêutica para o tratamento de doença imune |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US7465445B2 (pt) |
| EP (1) | EP1125585B1 (pt) |
| JP (1) | JP3871503B2 (pt) |
| KR (2) | KR100609441B1 (pt) |
| CN (2) | CN101028519B (pt) |
| AT (1) | ATE517925T1 (pt) |
| AU (1) | AU6865000A (pt) |
| BR (1) | BR0007047A (pt) |
| CA (1) | CA2348954C (pt) |
| CZ (1) | CZ304013B6 (pt) |
| HK (1) | HK1040489A1 (pt) |
| HU (1) | HU228575B1 (pt) |
| ID (1) | ID30042A (pt) |
| IL (2) | IL142691A0 (pt) |
| NO (2) | NO332264B1 (pt) |
| NZ (1) | NZ529577A (pt) |
| RU (1) | RU2203682C2 (pt) |
| SK (1) | SK288074B6 (pt) |
| TR (1) | TR200101205T1 (pt) |
| WO (1) | WO2001015732A1 (pt) |
| ZA (1) | ZA200103314B (pt) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7112655B1 (en) | 1997-02-27 | 2006-09-26 | Japan Tobacco, Inc. | JTT-1 protein and methods of inhibiting lymphocyte activation |
| JP3521382B2 (ja) | 1997-02-27 | 2004-04-19 | 日本たばこ産業株式会社 | 細胞間接着及びシグナル伝達を媒介する細胞表面分子 |
| US7435796B1 (en) | 1999-02-03 | 2008-10-14 | Amgen Inc. | Antibodies which bind B7RP1 |
| DK2332978T3 (da) | 1999-02-03 | 2014-06-23 | Amgen Inc | Nye polypeptider, der er involveret ved et immunrespons |
| US7708993B2 (en) | 1999-02-03 | 2010-05-04 | Amgen Inc. | Polypeptides involved in immune response |
| US8624010B1 (en) | 1999-02-03 | 2014-01-07 | Steven K. Yoshinaga | Nucleic acids encoding B7RP1 |
| JP3871503B2 (ja) | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
| JP4210454B2 (ja) * | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
| US7879840B2 (en) | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| US7718644B2 (en) | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
| JP3597140B2 (ja) * | 2000-05-18 | 2004-12-02 | 日本たばこ産業株式会社 | 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途 |
| US7220822B2 (en) * | 2000-11-22 | 2007-05-22 | The Ohio State University | CD28 mimetics for blocking T cell mediated immune reactions |
| JP4212278B2 (ja) | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
| US8710045B2 (en) | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
| US7704990B2 (en) | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| US20080279851A1 (en) * | 2007-05-07 | 2008-11-13 | Medlmmune, Llc | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| EP2691419B1 (en) * | 2011-03-31 | 2016-11-09 | INSERM - Institut National de la Santé et de la Recherche Médicale | Antibodies directed against icos and uses thereof |
| DE102011006809A1 (de) | 2011-04-05 | 2012-10-11 | Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg | Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten |
| EP2717887B1 (en) | 2011-06-09 | 2017-12-27 | University of Florida Research Foundation, Inc. | Methods for treating or preventing graft versus host disease |
| EP2892928B1 (en) * | 2012-09-03 | 2018-05-30 | INSERM - Institut National de la Santé et de la Recherche Médicale | Antibodies directed against icos for treating graft-versus-host disease |
| JOP20140087B1 (ar) | 2013-03-13 | 2021-08-17 | Amgen Inc | بروتينات مخصصة ل baff و b7rp1 وإستخداماتها |
| US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| MX363780B (es) | 2015-12-03 | 2019-04-03 | Glaxosmithkline Ip Dev Ltd | Dinucleótidos de purina cíclica como moduladores del estimulador de los genes de interferón. |
| WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
| WO2017153952A1 (en) | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | 5-sulfamoyl-2-hydroxybenzamide derivatives |
| AU2017247806B2 (en) | 2016-04-07 | 2019-11-14 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
| NZ745957A (en) | 2016-04-07 | 2020-07-31 | Glaxosmithkline Ip Dev Ltd | Heterocyclic amides useful as protein modulators |
| CN109328188A (zh) | 2016-05-05 | 2019-02-12 | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | Zeste增强子同源物2抑制剂 |
| WO2018029474A2 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
| WO2017220990A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 antibodies |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| KR20190028540A (ko) | 2016-07-20 | 2019-03-18 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Perk 억제제로서의 이소퀴놀린 유도체 |
| EP3497128A2 (en) | 2016-08-09 | 2019-06-19 | Kymab Limited | Anti-icos antibodies |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| BR112019012901A2 (pt) | 2016-12-22 | 2020-01-07 | Daiichi Sankyo Company, Limited | Anticorpo ou fragmento de ligação a antígeno do anticorpo, polinucleotídeo, vetor, célula, métodos para produzir um anticorpo ou um fragmento de ligação a antígeno do anticorpo e uma molécula que se ligue ao cd3 humano e ao cd3 de macaco cinomolgo, composição farmacêutica, e, molécula |
| JP2020509009A (ja) | 2017-02-27 | 2020-03-26 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | キナーゼ阻害剤としての複素環式アミド |
| TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| BR112019025257A2 (pt) | 2017-06-09 | 2020-09-29 | Glaxosmithkline Intellectual Property Development Limited | método para tratar câncer, e, anticorpo anti-icos ou porção de ligação ao antígeno do mesmo e um anticorpo anti-ox40 ou porção de ligação ao antígeno do mesmo |
| CA3066048A1 (en) | 2017-06-09 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
| JP2020522541A (ja) | 2017-06-09 | 2020-07-30 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 癌を治療するためのｉｃｏｓアゴニストおよびｏｘ４０アゴニストでの組み合わせ療法 |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| WO2019021208A1 (en) | 2017-07-27 | 2019-01-31 | Glaxosmithkline Intellectual Property Development Limited | USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS |
| WO2019053617A1 (en) | 2017-09-12 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | CHEMICAL COMPOUNDS |
| CN111094353A (zh) | 2017-09-14 | 2020-05-01 | 葛兰素史密斯克莱知识产权发展有限公司 | 用于癌症的组合治疗 |
| CA3077337A1 (en) | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (sting) |
| WO2019069269A1 (en) | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | INTERFERON GENE STIMULATOR MODULATORS USEFUL IN THE TREATMENT OF HIV |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| US11629189B2 (en) | 2017-12-19 | 2023-04-18 | Kymab Limited | Bispecific antibody for ICOS and PD-L1 |
| GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
| BR112020023451A2 (pt) | 2018-05-31 | 2021-02-23 | Glaxosmithkline Intellectual Property Development Limited | terapia combinada |
| BR112020023459A2 (pt) | 2018-05-31 | 2021-02-23 | Glaxosmithkline Intellectual Property Development Limited | terapia combinada com proteínas de ligação a icos e inibidores de arginina metiltransferase |
| WO2019241730A2 (en) | 2018-06-15 | 2019-12-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
| WO2020031087A1 (en) | 2018-08-06 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
| US20210324081A1 (en) | 2018-10-22 | 2021-10-21 | Glaxosmithkline Intellectual Property Development Limited | Dosing |
| MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
| GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| WO2021018941A1 (en) | 2019-07-31 | 2021-02-04 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating cancer |
| WO2021043961A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy |
| WO2021046293A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and tremelimumab |
| AU2020355614A1 (en) | 2019-09-27 | 2022-04-14 | Glaxosmithkline Intellectual Property Development Limited | Antigen binding proteins |
| EP4076434A1 (en) | 2019-12-17 | 2022-10-26 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| CA3171597A1 (en) | 2020-04-14 | 2021-10-21 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer |
| WO2021209357A1 (en) | 2020-04-14 | 2021-10-21 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies |
| AU2021256925A1 (en) | 2020-04-14 | 2022-11-03 | Ares Trading S.A. | Combination treatment for cancer based upon an ICOS antibody and a PD-L1 antibody TGF-beta-receptor fusion protein |
| GB202007099D0 (en) | 2020-05-14 | 2020-07-01 | Kymab Ltd | Tumour biomarkers for immunotherapy |
| US20230355804A1 (en) | 2020-06-29 | 2023-11-09 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| MX2023010067A (es) | 2021-03-02 | 2023-09-06 | Glaxosmithkline Ip Dev Ltd | Piridinas sustituidas como inhibidores de dnmt1. |
| WO2022208353A1 (en) | 2021-03-31 | 2022-10-06 | Glaxosmithkline Intellectual Property Development Limited | Antigen binding proteins and combinations thereof |
| WO2022212784A1 (en) | 2021-03-31 | 2022-10-06 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| CA3219336A1 (en) | 2021-05-18 | 2022-11-24 | Kymab Limited | Uses of anti-icos antibodies |
| GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
| CA3224374A1 (en) | 2021-06-29 | 2023-01-05 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| WO2023222854A1 (en) | 2022-05-18 | 2023-11-23 | Kymab Limited | Uses of anti-icos antibodies |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5506126A (en) | 1988-02-25 | 1996-04-09 | The General Hospital Corporation | Rapid immunoselection cloning method |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6641809B1 (en) | 1990-03-26 | 2003-11-04 | Bristol-Myers Squibb Company | Method of regulating cellular processes mediated by B7 and CD28 |
| US5770197A (en) | 1991-06-27 | 1998-06-23 | Bristol-Myers Squibb Company | Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules |
| JP3162438B2 (ja) | 1991-09-12 | 2001-04-25 | 住友製薬株式会社 | 高感度特異的抗体測定法 |
| US5484892A (en) | 1993-05-21 | 1996-01-16 | Dana-Farber Cancer Institute, Inc. | Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells |
| US6719972B1 (en) | 1994-06-03 | 2004-04-13 | Repligen Corporation | Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies |
| US5747461A (en) | 1994-07-26 | 1998-05-05 | Markov; Angel K. | Synergistic administration of cyclosporine and fructose diphosphate |
| US6440418B1 (en) * | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
| US5914112A (en) | 1996-01-23 | 1999-06-22 | Genentech, Inc. | Anti-CD18 antibodies in stroke |
| DK0877626T3 (da) | 1996-01-23 | 2002-12-30 | Univ Vermont | Anti-CD18 antistoffer til anvendelse mod slagtilfælde |
| CA2266346A1 (en) | 1996-09-18 | 1998-03-26 | Zetesis S.P.A. | Use of proteins as agents against autoimmune diseases |
| DE69739725D1 (de) | 1996-11-08 | 2010-02-11 | Biogen Idec Inc | Identifikation von bindungs- interaktionen zwischen gewissen antikorpern und den humanen costimulatorischen antigenen b7.1 (cd80) und b7.2 (cd28) |
| CA2194814A1 (en) * | 1997-01-10 | 1998-07-10 | Terry L. Delovitch | Stimulation of protective t cells to prevent autoimmune disease |
| AU4145597A (en) | 1997-02-20 | 1998-09-09 | Cedars-Sinai Medical Center | Ulcerative colitis panca secretory vesicle antigen and methods of using sa me |
| US7112655B1 (en) | 1997-02-27 | 2006-09-26 | Japan Tobacco, Inc. | JTT-1 protein and methods of inhibiting lymphocyte activation |
| JP3521382B2 (ja) | 1997-02-27 | 2004-04-19 | 日本たばこ産業株式会社 | 細胞間接着及びシグナル伝達を媒介する細胞表面分子 |
| NZ500078A (en) | 1997-04-07 | 2001-10-26 | Genentech Inc | Humanized anti-VEGF antibodies and their use in inhibiting VEGF-induced angiogenesis in mammals |
| CN1202864C (zh) * | 1997-05-17 | 2005-05-25 | 拜奥根有限公司 | Cd40:cd154结合阻断物在制备预防逆适应性免疫应答,特别是移植物排斥反应的药物中的用途 |
| DE19821060A1 (de) | 1997-09-23 | 1999-04-15 | Bundesrepublik Deutschland Let | Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung |
| US7259247B1 (en) | 1997-09-23 | 2007-08-21 | Bundersrespublik Deutschaland Letztvertreten Durch Den Direktor Des Robert-Koch-Institutes | Anti-human T-cell costimulating polypeptide monoclonal antibodies |
| JPH11228442A (ja) | 1998-02-09 | 1999-08-24 | Cypros Pharmaceut Corp | 臓器移植後のシクロスポリン投与量を低減するためのフルクトース二リン酸の使用 |
| JP2000154151A (ja) | 1998-09-14 | 2000-06-06 | Kyo Jo | 免疫抑制剤 |
| AU767241B2 (en) | 1998-09-14 | 2003-11-06 | Qiang Xu | Immunosuppressive agents |
| JP2003532370A (ja) | 1998-10-07 | 2003-11-05 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 新規なＴｈ２特異的分子およびその使用方法 |
| DK2332978T3 (da) | 1999-02-03 | 2014-06-23 | Amgen Inc | Nye polypeptider, der er involveret ved et immunrespons |
| WO2000067788A2 (en) | 1999-05-06 | 2000-11-16 | Genetics Institute, Inc. | Use of soluble costimulatory molecules to enhance immune responses |
| US6613327B1 (en) | 1999-07-28 | 2003-09-02 | Genetics Institute, Inc. | Methods of preventing immune-mediated abortion by inhibiting a CD28-mediated costimulatory signal |
| AU6458400A (en) | 1999-08-11 | 2001-03-13 | Isis Innovation Limited | Nucleic acid, polypeptides, assays, therapeutic methods and means |
| JP4210454B2 (ja) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
| JP3871503B2 (ja) | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
| JP2003508088A (ja) | 1999-09-03 | 2003-03-04 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ５２個のヒト分泌タンパク質 |
| EP1218504B1 (en) | 1999-09-21 | 2007-07-11 | Genetics Institute, LLC | Gl50 molecules and uses therefor |
| CA2386641A1 (en) | 1999-10-29 | 2001-05-10 | Human Genome Sciences, Inc. | 32 human secreted proteins |
| WO2001064704A1 (en) | 2000-03-02 | 2001-09-07 | Mayo Foundation For Medical Education And Research | hB7-H2, A NOVEL CO-STIMULATORY MOLECULE |
| JP3597140B2 (ja) | 2000-05-18 | 2004-12-02 | 日本たばこ産業株式会社 | 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途 |
| WO2002044364A2 (en) | 2000-11-28 | 2002-06-06 | Amgen Inc. | Polypeptides involved in immune response |
| JP4212278B2 (ja) | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
-
2000
- 2000-08-29 JP JP2000258470A patent/JP3871503B2/ja not_active Expired - Fee Related
- 2000-08-30 TR TR2001/01205T patent/TR200101205T1/xx unknown
- 2000-08-30 IL IL14269100A patent/IL142691A0/xx unknown
- 2000-08-30 HU HU0200994A patent/HU228575B1/hu not_active IP Right Cessation
- 2000-08-30 RU RU2001114516/14A patent/RU2203682C2/ru not_active IP Right Cessation
- 2000-08-30 BR BR0007047-5A patent/BR0007047A/pt active Search and Examination
- 2000-08-30 SK SK732-2001A patent/SK288074B6/sk not_active IP Right Cessation
- 2000-08-30 CN CN2006101006481A patent/CN101028519B/zh not_active Expired - Fee Related
- 2000-08-30 CN CN00802420A patent/CN1359302A/zh active Pending
- 2000-08-30 KR KR1020017005279A patent/KR100609441B1/ko not_active IP Right Cessation
- 2000-08-30 AT AT00956800T patent/ATE517925T1/de not_active IP Right Cessation
- 2000-08-30 CZ CZ20011720A patent/CZ304013B6/cs not_active IP Right Cessation
- 2000-08-30 KR KR10-2004-7001435A patent/KR20040028960A/ko not_active Application Discontinuation
- 2000-08-30 NZ NZ529577A patent/NZ529577A/en not_active IP Right Cessation
- 2000-08-30 WO PCT/JP2000/005868 patent/WO2001015732A1/ja active IP Right Grant
- 2000-08-30 CA CA2348954A patent/CA2348954C/en not_active Expired - Fee Related
- 2000-08-30 EP EP00956800A patent/EP1125585B1/en not_active Expired - Lifetime
- 2000-08-30 ID IDW00200101165A patent/ID30042A/id unknown
- 2000-08-30 AU AU68650/00A patent/AU6865000A/en not_active Abandoned
-
2001
- 2001-04-19 IL IL142691A patent/IL142691A/en not_active IP Right Cessation
- 2001-04-24 ZA ZA200103314A patent/ZA200103314B/en unknown
- 2001-04-27 NO NO20012105A patent/NO332264B1/no not_active IP Right Cessation
-
2002
- 2002-02-22 HK HK02101307.4A patent/HK1040489A1/zh unknown
-
2003
- 2003-12-05 US US10/729,880 patent/US7465445B2/en not_active Expired - Fee Related
-
2008
- 2008-08-26 NO NO20083674A patent/NO20083674L/no not_active Application Discontinuation
- 2008-11-11 US US12/268,832 patent/US7998478B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0007047A (pt) | Composição farmacêutica para o tratamento de doença imune | |
| Haneberg et al. | Induction of specific immunoglobulin A in the small intestine, colon-rectum, and vagina measured by a new method for collection of secretions from local mucosal surfaces | |
| EA200401473A1 (ru) | Предотвращение и лечение амилоидогенного заболевания | |
| Fouda et al. | Evaluation of the effect of hydroalcoholic extract of Zingiber officinale rhizomes in rat collagen‐induced arthritis | |
| BRPI9710372B8 (pt) | composto, e, composição farmacêutica. | |
| BR0116052A (pt) | imidazoquinolinas substituìdas por éter arìlico | |
| DE60125797D1 (de) | Impfstoffzusammesetzung | |
| BR9914044A (pt) | ésteres tetrahidropirido | |
| BR9915553A (pt) | Amidas de ácido antranìlico e seu emprego como medicamento | |
| IL158088A0 (en) | Remedies for inflammatory bowel diseases | |
| ITMI951359A0 (it) | Formulazioni farmaceutiche e dietetiche per la profilassi e la cura di affezioni gastrointestinali | |
| BR9913020A (pt) | Composto, composição farmacêutica, uso de um composto, uso de um inibidor da molécula de adesão celular na fabricação de medicamento, uso de éster de éter metil nonaetileno glicol do ácido (e) -4- (1,3 - bis (ciclo-hexilmetil) - 1,2,3,6-tetraidro-2,6-dioxo-9h- - purin-8-il)-cinâmico, e, processos para tratar condições inflamatórias, distúrbios imune, ferimento de tecido, doenças infecciosas, câncer e qualquer distúrbio em que a adesão alterada de leucócitos contribui para a patogênese da doença, para tratar doença periodontal e para preparar os compostos ou solvatos destes | |
| DE60030568D1 (de) | Withania somnifera zusammensetzung | |
| ATE506959T1 (de) | Verwendung von il-18 inhibitoren | |
| EA200301187A1 (ru) | Применение азитромицина для производства лекарственного средства для лечения неинфекционных воспалительных заболеваний | |
| BR0009531A (pt) | Polìmeros de imunomodulação | |
| BRPI0411176A (pt) | combinação farmacêutica consistindo de modafinil e outra droga | |
| BR9808008A (pt) | Processo para o tratamento anticoagulante e/ou antitrombótico de um ser humano ou outro paciente animal de sangue quente, usos de um oligossacarìdeo sulfatado e na fabricação de um medicamento, e, composição farmacêutica ou veterinária para tratamento anticoagulante e/ou antitrombótico. | |
| BR9911151A (pt) | Inibidores do fator de transcrição nf-kb | |
| ES2054115T3 (es) | Fenilhidrazonas, su fabricacion y medicamentos y productos cosmeticos fabricados a partir de estas. | |
| DK0787135T3 (da) | Vandopløslige derivater af epipodophyllotoxin, fremgangsmåde til fremstilling deraf og anvendelse som et lægemiddel til beh | |
| NO844889L (no) | Oksicam-derivater og fremgangsmaate til deres fremstilling | |
| EE200200088A (et) | Bis-sulfoonamiidide kasutamine ravimite valmistamiseks, mis on ette nähtud hüperlipideemia ärahoidmiseks või raviks | |
| BR0209648A (pt) | Combinação compreendendo um inibidor de p-gp e uma droga antiepiléptica | |
| BR9808392A (pt) | Uso de anticorpos de aves, e, processo para tratar infecções do trato respiratório. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 16A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B07F | Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette] |